News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
An entire lot of the male erectile dysfunction drug The Red Pill is being pulled out of the market following the discovery that it contains some traces of tadalafil.
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.
Statistically significant weight loss and liver fat reduction were seen across all dosage groups—with no changes to diet or exercise.
It’s not likely that the FDA will give the cancer drug sintilimab immediate attention, since the research was conducted exclusively in China.
Endevica Bio isn’t trying to cure cancer. Instead, it is focused on improving cancer patients’ quality of life and preventing deaths.
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
The vaccine delivered more than $12 billion in revenue to Pfizer and the company expects those earnings to vastly increase this year to $32 billion.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
WuXi Biologics was amongst those on the list, with the U.S. stating that it was unable to verify the legitimacy and reliability of the company in its use of U.S. exports.